Compare Stocks: NKTR, PRAX, SYRE, and IONS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IONS Ionis Pharmaceuticals	$43.93 -4.0%	$55.33	$43.01 ▼ $86.74	$7.60B	0.42	3.84 million shs	3.54 million shs
NKTR Nektar Therapeutics	$57.66 -5.4%	$71.37	$33.40 ▼ $109.00	$2.08B	1.14	929,940 shs	1.83 million shs
PRAX Praxis Precision Medicines	$282.12 -6.2%	$337.62	$46.99 ▼ $392.70	$8.39B	2.76	350,754 shs	1.01 million shs
SYRE Spyre Therapeutics	$88.17 -4.1%	$97.32	$15.49 ▼ $110.18	$8.09B	2.99	1.34 million shs	918,763 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IONS Ionis Pharmaceuticals	-3.98%	-2.03%	-29.19%	-43.92%	-29.79%
NKTR Nektar Therapeutics	-5.43%	-14.43%	-21.75%	-7.04%	-3.26%
PRAX Praxis Precision Medicines	-6.16%	-8.70%	-23.34%	-13.95%	+480.49%
SYRE Spyre Therapeutics	-4.13%	-3.29%	-17.33%	-0.56%	+450.37%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IONS Ionis Pharmaceuticals	$43.93 -4.0%	$55.33	$43.01 ▼ $86.74	$7.60B	0.42	3.84 million shs	3.54 million shs
NKTR Nektar Therapeutics	$57.66 -5.4%	$71.37	$33.40 ▼ $109.00	$2.08B	1.14	929,940 shs	1.83 million shs
PRAX Praxis Precision Medicines	$282.12 -6.2%	$337.62	$46.99 ▼ $392.70	$8.39B	2.76	350,754 shs	1.01 million shs
SYRE Spyre Therapeutics	$88.17 -4.1%	$97.32	$15.49 ▼ $110.18	$8.09B	2.99	1.34 million shs	918,763 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IONS Ionis Pharmaceuticals	-3.98%	-2.03%	-29.19%	-43.92%	-29.79%
NKTR Nektar Therapeutics	-5.43%	-14.43%	-21.75%	-7.04%	-3.26%
PRAX Praxis Precision Medicines	-6.16%	-8.70%	-23.34%	-13.95%	+480.49%
SYRE Spyre Therapeutics	-4.13%	-3.29%	-17.33%	-0.56%	+450.37%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IONS Ionis Pharmaceuticals	2.73	Moderate Buy	$90.50	106.01% Upside
NKTR Nektar Therapeutics	2.77	Moderate Buy	$138.50	140.20% Upside
PRAX Praxis Precision Medicines	2.95	Moderate Buy	$612.42	117.08% Upside
SYRE Spyre Therapeutics	2.87	Moderate Buy	$109.69	24.41% Upside

Current Analyst Ratings Breakdown

Latest NKTR, PRAX, SYRE, and IONS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	NKTR Nektar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$80.00 ➝ $50.00
9/22/2026	IONS Ionis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$76.00 ➝ $70.00
9/16/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
9/15/2026	IONS Ionis Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$89.00 ➝ $80.00
9/9/2026	IONS Ionis Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$90.00 ➝ $85.00
9/9/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$178.00
9/9/2026	SYRE Spyre Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$123.00
9/8/2026	IONS Ionis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$84.00
9/8/2026	IONS Ionis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$110.00 ➝ $104.00
9/8/2026	IONS Ionis Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/8/2026	IONS Ionis Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Perform	$61.00 ➝ $54.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IONS Ionis Pharmaceuticals	$944M	7.73	N/A	N/A	$3.02 per share	14.55
NKTR Nektar Therapeutics	$55.23M	35.64	N/A	N/A	$4.41 per share	13.07
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	$34.85 per share	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	$7.21 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)
NKTR Nektar Therapeutics	-$164.08M	-$6.70	N/A	N/A	N/A	-287.84%	-37.87%	-25.67%	11/5/2026 (Estimated)
PRAX Praxis Precision Medicines	-$303.27M	-$12.93	N/A	N/A	N/A	N/A	-34.15%	-32.42%	11/9/2026 (Estimated)
SYRE Spyre Therapeutics	-$155.20M	-$1.95	N/A	N/A	N/A	N/A	-30.74%	-22.23%	11/3/2026 (Estimated)

Latest NKTR, PRAX, SYRE, and IONS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	-$1.23	+$0.74	-$1.23	$10.43 million	$10.13 million
8/6/2026	Q2 2026	PRAX Praxis Precision Medicines	-$3.67	-$2.87	+$0.80	-$2.87	$1.25 million	N/A
8/4/2026	Q2 2026	SYRE Spyre Therapeutics	-$0.7589	-$0.36	+$0.3989	-$0.36	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
SYRE Spyre Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
NKTR Nektar Therapeutics	N/A	10.42	10.42
PRAX Praxis Precision Medicines	N/A	15.73	15.73
SYRE Spyre Therapeutics	N/A	18.53	18.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IONS Ionis Pharmaceuticals	93.86%
NKTR Nektar Therapeutics	75.88%
PRAX Praxis Precision Medicines	67.84%
SYRE Spyre Therapeutics	80.39%

Insider Ownership

Company	Insider Ownership
IONS Ionis Pharmaceuticals	1.81%
NKTR Nektar Therapeutics	2.50%
PRAX Praxis Precision Medicines	3.00%
SYRE Spyre Therapeutics	15.69%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
NKTR Nektar Therapeutics	63	34.14 million	33.29 million	Optionable
PRAX Praxis Precision Medicines	110	27.92 million	27.08 million	Optionable
SYRE Spyre Therapeutics	112	87.94 million	74.14 million	Optionable

NKTR, PRAX, SYRE, and IONS Headlines

Recent News About These Companies

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Moderate Buy" by Brokerages

September 20, 2026 | americanbankingnews.com

Spyre (SYRE) Clears Monotherapy Phase for IBD Portfolio, Setting Up Combination Tests

September 17, 2026 | finance.yahoo.com

Financial Contrast: Spyre Therapeutics (NASDAQ:SYRE) vs. Genmab A/S (NASDAQ:GMAB)

September 17, 2026 | americanbankingnews.com

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Rating of "Moderate Buy" from Analysts

September 15, 2026 | marketbeat.com

California State Teachers Retirement System Increases Stake in Spyre Therapeutics, Inc. $SYRE

September 15, 2026 | marketbeat.com

Engineers Gate Manager LP Takes $3.42 Million Position in Spyre Therapeutics, Inc. $SYRE

September 14, 2026 | marketbeat.com

11,250 Shares in Spyre Therapeutics, Inc. $SYRE Acquired by VIRGINIA RETIREMENT SYSTEMS ET Al

September 14, 2026 | marketbeat.com

Spyre Therapeutics (SYRE) Reports SPY003 Endoscopic Improvement. Can Randomized Testing Confirm It?

September 10, 2026 | insidermonkey.com

Squarepoint Ops LLC Invests $12.39 Million in Spyre Therapeutics, Inc. $SYRE

September 10, 2026 | marketbeat.com

Allianz Asset Management GmbH Takes Position in Spyre Therapeutics, Inc. $SYRE

September 10, 2026 | marketbeat.com

Spyre Therapeutics, Inc. (SYRE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

September 9, 2026 | seekingalpha.com

Spyre Therapeutics (SYRE) Stock Surges as Guggenheim Declares It Top Biotech Following UC Trial Results

September 9, 2026 | blockonomi.com

Spyre's Anti-IL-23 Antibody Meets Goal in Ulcerative Colitis Study

September 9, 2026 | zacks.com

Wedbush Reiterates "Outperform" Rating for Spyre Therapeutics (NASDAQ:SYRE)

September 9, 2026 | marketbeat.com

Maven Securities LTD Invests $3.55 Million in Spyre Therapeutics, Inc. $SYRE

September 9, 2026 | marketbeat.com

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD ...

September 8, 2026 | markets.businessinsider.com

Spyre Therapeutics Reports Positive Phase 2 SPY003 Data In Ulcerative Colitis

September 8, 2026 | rttnews.com

Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis

September 8, 2026 | finance.yahoo.com

Spyre Therapeutics' (SYRE) Buy Rating Reiterated at BTIG Research

September 8, 2026 | marketbeat.com

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down - Here's What Happened

September 8, 2026 | marketbeat.com

Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations

September 8, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR, PRAX, SYRE, and IONS Company Descriptions

Ionis Pharmaceuticals NASDAQ:IONS

$43.93 -1.82 (-3.98%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$43.78 -0.15 (-0.35%)

As of 05:40 AM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Nektar Therapeutics NASDAQ:NKTR

$57.66 -3.31 (-5.43%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$58.10 +0.44 (+0.77%)

As of 05:43 AM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Praxis Precision Medicines NASDAQ:PRAX

$282.12 -18.53 (-6.16%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$282.50 +0.38 (+0.13%)

As of 04:57 AM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Spyre Therapeutics NASDAQ:SYRE

$88.17 -3.80 (-4.13%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$88.25 +0.08 (+0.09%)

As of 04:35 AM Eastern

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NKTR, PRAX, SYRE, and IONS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NKTR, PRAX, SYRE, and IONS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NKTR, PRAX, SYRE, and IONS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR, PRAX, SYRE, and IONS Company Descriptions

Ionis Pharmaceuticals NASDAQ:IONS

Nektar Therapeutics NASDAQ:NKTR

Praxis Precision Medicines NASDAQ:PRAX

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NKTR, PRAX, SYRE, and IONS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NKTR, PRAX, SYRE, and IONS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NKTR, PRAX, SYRE, and IONS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKTR, PRAX, SYRE, and IONS Company Descriptions

Ionis Pharmaceuticals NASDAQ:IONS

Nektar Therapeutics NASDAQ:NKTR

Praxis Precision Medicines NASDAQ:PRAX

Spyre Therapeutics NASDAQ:SYRE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools